ArticleJournal of cardiovascular translational research2026
Mitochondrial Ferritin in Subclinical Anthracycline-Induced Cardiotoxicity in Humans: A Pilot Study.
Article in Journal of cardiovascular translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the effects of anthracyclines on mitochondrial ferritin (MtFt) expression in primary murine cardiomyocytes and in cancer patients. MtFt expression was first evaluated in murine cardiomyocytes before and after doxorubicin exposure. Subsequently, MtFt levels were assessed in peripheral blood cells of 26 cancer patients at baseline, at the end of treatment, and 12 months after the first cycle, together with high-sensitivity troponin T (hsTnT), N-terminal pro-brain natriuretic peptide (NT-proBNP), and left ventricular ejection fraction (LVEF). Doxorubicin-treated murine cardiomyocytes exhibited increased MtFt expression compared with untreated cells. No patient developed clinically relevant cardiotoxicity. A weak but significant inverse association was observed between MtFt levels and LVEF at the end of treatment. Multivariable linear regression showed no significant predictive effect of hsTnT, NT-proBNP, or time on MtFt changes, although MtFt levels tended to decrease and hsTnT levels to increase over time.
Indexed as
Identifiers
42771092What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.